Wewer Albrechtsen, Nicolai J. http://orcid.org/0000-0003-4230-5753
Holst, Jens J.
Cherrington, Alan D.
Finan, Brian
Gluud, Lise Lotte
Dean, E. Danielle
Campbell, Jonathan E.
Bloom, Stephen R.
Tan, Tricia M.-M.
Knop, Filip K. http://orcid.org/0000-0002-2495-5034
Müller, Timo D.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GRK 2816/1, SFB1123, TRR152, TRR296)
Novo Nordisk Fonden (NNF21OC0072718)
European Foundation for the Study of Diabetes (NNF21SA0072746)
H2020 European Research Council (101044445)
Deutsche Diabetes Gesellschaft
Danmarks Frie Forskningsfond (1052-00003B)
National Institute for Health and Care Research (R01DK132669)
Article History
Received: 17 February 2023
Accepted: 18 April 2023
First Online: 27 June 2023
Acknowledgements
: We acknowledge the many contributors to the glucagon field, including members from our own groups, without whom this review would not have been made possible. This review was based on the international glucagon conference, entitled ‘A hundred years with glucagon and a hundred more’, held in Copenhagen, Denmark, in November 2022. Figures were created with BioRender.com.
: The review is supported by an unrestricted grant from the Novo Nordic Foundation (NNF21OC0072718) to NJWA in relation to hosting the international glucagon conference in Copenhagen, 1–2 November 2022, in the celebration of glucagon’s 100 year birthday. Furthermore, work in the authors’ laboratories is supported by several funding agencies: NJWA is supported by a grant from European Foundation for the Study of Diabetes Future Leader Award (NNF21SA0072746) and a grant from Independent Research Fund Denmark, Sapere Aude (1052–00003B); EDD is supported by the National Institute of Health (R01DK132669 and R01DK117147); and TDM received funding from the German Research Foundation (DFG TRR296, TRR152, SFB1123 and GRK 2816/1), the German Center for Diabetes Research (DZD e.V.) and the European Research Council ERC-CoG Trusted no. 101044445.
: NJWA has received funding from, and served on scientific advisory panels and/or speakers’ bureaus for Boehringer Ingelheim, MSD/MERCK, Novo Nordisk and Mercodia. JJH has served on scientific advisory panels and received speaker fees for Novo Nordisk. ADC’s external relationships include consulting, research advisory boards and research contract: Abvance; Adipo-Pharma; Cellular Longevity, Inc. dba Loyal; Diakard/Diabetica; Fractyl Laboratories, Inc; Novo Nordisk, Inc; Sekki Bio; Senda Biosciences, Inc; Sensulin Labs, LLC; Thetis Pharmaceuticals, LLC; vTv Therapeutics. BF is employed at Novo Nordisk. LLG has received funding, consultant fees from and/or served on scientific advisory panels for Novo Nordisk, Gilead, Becton Dickinson, Sobi, Pfizer and AstraZeneca. JEC receives research funding from Novo Nordisk and Eli Lilly. SRB and TM-MT are shareholders in Zihipp, Ltd. FKK has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Pharmacosmos, Sanofi, ShouTi, Zealand Pharma and Zucara; and is a minority shareholder in Antag Therapeutics and co-owner of the weight loss clinic Medicinsk Vægttabsbehandling ApS. TDM has received funding from Novo Nordisk. The remaining author (DD) declares that there are no relationships or activities that might bias, or be perceived to bias, their work.
: NJWA, JJH and TDM drafted the first version of the review. ADC, BF, LLG, EDD, JEC, SRB, TM-MT and FKK revised the review for important intellectual content. NJWA drafted figures. All authors approved the version to be published.
Free to read: This content has been made available to all.